用于治疗或预防冠状病毒感染的蛋白酶抑制剂。
Protease Inhibitors for Treating or Preventing Coronavirus Infection.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2023 Oct 6;14(11):1489-1490. doi: 10.1021/acsmedchemlett.3c00417. eCollection 2023 Nov 9.
Abstract
Provided herein are novel compounds as protease inhibitors, pharmaceutical compositions, use of such compounds in treating or preventing coronavirus infection, and processes for preparing such compounds.
摘要
本文提供了作为蛋白酶抑制剂的新型化合物、药物组合物、此类化合物在治疗或预防冠状病毒感染中的用途以及制备此类化合物的方法。
相似文献
1
Protease Inhibitors for Treating or Preventing Coronavirus Infection.用于治疗或预防冠状病毒感染的蛋白酶抑制剂。
ACS Med Chem Lett. 2023 Oct 6;14(11):1489-1490. doi: 10.1021/acsmedchemlett.3c00417. eCollection 2023 Nov 9.
2
Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections.用于治疗病毒感染，特别是冠状病毒感染的新型木瓜蛋白酶样蛋白酶抑制剂。
ACS Med Chem Lett. 2024 Jul 23;15(8):1186-1187. doi: 10.1021/acsmedchemlett.4c00331. eCollection 2024 Aug 8.
3
Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19.用于预防新型冠状病毒（SARS-CoV-2）复制及治疗新冠肺炎（COVID-19）的新型化合物
ACS Med Chem Lett. 2023 Aug 9;14(9):1150-1151. doi: 10.1021/acsmedchemlett.3c00323. eCollection 2023 Sep 14.
4
Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection.新型呋吡啶和呋嘧啶化合物作为用于治疗疟疾和病毒感染的PI4K抑制剂
ACS Med Chem Lett. 2024 May 31;15(6):779-780. doi: 10.1021/acsmedchemlett.4c00229. eCollection 2024 Jun 13.
5
Discovery of Novel Cysteine Protease Inhibitors for the Treatment of Coronavirus (COVID-19).新型半胱氨酸蛋白酶抑制剂治疗冠状病毒（COVID-19）的发现。
Curr Med Chem. 2024;31(9):1165-1169. doi: 10.2174/0929867330666230519163305.
6
Novel Compounds as TEAD Inhibitors for Treating Cancer.用于治疗癌症的新型TEAD抑制剂化合物
ACS Med Chem Lett. 2023 Aug 22;14(9):1152-1153. doi: 10.1021/acsmedchemlett.3c00346. eCollection 2023 Sep 14.
7
Fused Bicyclic Heteroaryl Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂的稠合双环杂芳基化合物
ACS Med Chem Lett. 2023 Jun 6;14(7):895-896. doi: 10.1021/acsmedchemlett.3c00236. eCollection 2023 Jul 13.
8
Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.新型喹啉化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 May 26;14(6):707-708. doi: 10.1021/acsmedchemlett.3c00195. eCollection 2023 Jun 8.
9
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
10
Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma.新型吡唑并吡嗪化合物作为治疗胶质母细胞瘤的SHP2抑制剂
ACS Med Chem Lett. 2023 Sep 19;14(10):1336-1337. doi: 10.1021/acsmedchemlett.3c00393. eCollection 2023 Oct 12.
本文引用的文献
1
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.SARS-CoV 和 SARS-CoV-2 主要蛋白酶的结构与功能及其抑制作用：全面综述。
Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28.
2
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.2020 年至 2022 年 SARS-CoV-2 主蛋白酶抑制剂的研究进展。
Eur J Med Chem. 2023 Sep 5;257:115491. doi: 10.1016/j.ejmech.2023.115491. Epub 2023 May 22.
3
Maternal antiretroviral treatment for HIV infection and risk of small-for-gestational-age birth: A systematic review and meta-analysis of protease inhibitor-based treatment and timing of treatment.母亲抗逆转录病毒治疗人类免疫缺陷病毒感染与小于胎龄儿出生风险：基于蛋白酶抑制剂治疗和治疗时机的系统评价和荟萃分析。
Int J Antimicrob Agents. 2023 Jul;62(1):106823. doi: 10.1016/j.ijantimicag.2023.106823. Epub 2023 Apr 28.
4
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease.COVID-19 治疗药物：针对 SARS-CoV-2 主蛋白酶的小分子药物研发。
Drug Discov Today. 2023 Jun;28(6):103579. doi: 10.1016/j.drudis.2023.103579. Epub 2023 Apr 5.
5
Therapeutic potential of green tea catechin, (-)-epigallocatechin-3--gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases.绿茶儿茶素（-）-表没食子儿茶素-3-没食子酸酯（EGCG）在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染中的治疗潜力：与宿主/病毒蛋白酶的主要相互作用
Phytomed Plus. 2023 Feb;3(1):100402. doi: 10.1016/j.phyplu.2022.100402. Epub 2022 Dec 30.
6
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19.最近用于治疗 SARS-CoV-2 感染和 COVID-19 的药物开发和药物化学方法。
ChemMedChem. 2022 Nov 18;17(22):e202200440. doi: 10.1002/cmdc.202200440. Epub 2022 Oct 13.
Zotero 插件